Miller Anestesia

151. Pannu N, Nadim MK: An overview of drug-indu-

ced acute kidney injury. Crit Care Med 36:S216-

S223, 2008.

152. Wardle N: Acute renal failure in the 1980s: The

importance of septic shock and of endotoxemia.

Nephron 30:193-200, 1982.

153. Zager RA: Endotoxemia, renal hypoperfusion, and

fever: Interactive risk factors for aminoglycoside

and sepsis-associated acute renal failure. Am J

Kidney Dis 20:223-230, 1992.

154. Wetzels JF, Burke TJ, Schrier RW: Prevention and

attenuation of acute renal failure. Curr Opin

Nephrol Hypertens 1:133-140, 1992.

155. Clive D, Stoff J: Renal syndromes associated with

nonsteroidal anti-inflammatory drugs. N Engl J

Med 310:563-572, 1984.

156. Ahmad SR, Kortepeter C, Brinker A, et al: Renal

failure associated with the use of celecoxib and rofe-

coxib. Drug Saf 25:537-544, 2002.

157. Kunzendorf U,Walz G, Brockmoeller J, et al: Effects

of diltiazem upon metabolism and immunosu-

ppressive action of cyclosporine in kidney graft

recipients. Transplantation 52:280-284, 1991.

158. Neumayer HH,Kunzendorf U,Schreiber M: Protec-

tive effects of calcium antagonists in human renal

transplantation. Kidney Int Suppl 36:87-93, 1992.

159. Raichlin E, Bae JH, Khalpey Z, et al: Conversion to

sirolimus as primary immunosuppression attenua-

tes the progression of allograft vasculopathy after

cardiac transplantation. Circulation 116:2726-2733,

2007.

160. Parfrey PS, Griffiths SM, Barrett BJ, et al: Contrast

material–induced renal failure in patients with dia-

betes mellitus, renal insufficiency or both: A pros-

pective, controlled study. N Engl J Med 320:143,

1989.

161. Morcos SK: Prevention of contrast media nephro-

toxicity—the story so far. Clin Radiol 59:381-389,

2004.

162. Eisenberg RL, Bank WO, Hedgecock MW: Renal

failure after major angiography can be avoided with

hydration. Am J Radiol 136:859, 1981.

163. Tepel M, van der Giet M, Schwarzfeld C, et al: Pre-

vention of radiographic-contrast-agent–induced

reductions in renal function by acetylcysteine. N

Engl J Med 343:180-184, 2000.

164. Allaqaband S, Tumuluri R, Malik AM, et al: Pros-

pective randomized study of

-acetylcysteine,

fenoldopam, and saline for prevention of radiocon-

trast-induced nephropathy. Cathet Cardiovasc

Interv 57:279-283, 2002.

165. Briguori C, Manganelli F, Scarpato P, et al: Acetyl-

cysteine and contrast agent–associated nephrotoxi-

city. J Am Coll Cardiol 40:298-303, 2002.

166. Marenzi G,Assanelli E, Marana I, et al:

-acetylcys-

teine and contrast-induced nephropathy in primary

angioplasty. N Engl J Med 354:2773-2782, 2006.

167. Tumlin JA, Wang A, Murray PT, et al: Fenoldopam

mesylate blocks reductions in renal plasma flow

after radiocontrast dye infusion: A pilot trial in the

prevention of contrast nephropathy. Am Heart J

143:894-903, 2002.

168. Stone GW, McCullough PA, Tumlin JA, et al: Fenol-

dopam mesylate for the prevention of contrast-

induced nephropathy: A randomized controlled

trial. JAMA 290:2284-2291, 2003.

169. Gabow PA, Kaehny WD, Kelleher SP: The spectrum

of rhabdomyolysis. Medicine (Baltimore) 61:141,

1982.

170. Clyne DH, Kant KS, Pesce AJ, et al: Nephrotoxicity

of low molecular weight serum proteins: Physico-

chemical interactions between myoglobin, hemog-

lobin. Bence-Jones protein and Tamm-Horsfall

mucoprotein. Curr Prob Clin Biochem 9:299,

1979.

171. Ellinas PA, Rosner F: Rhabdomyolysis: Report of

eleven cases. J Natl Med Assoc 84:617-624, 1992.

172. Ron D, Taitelman U, Michaelson M, et al: Preven-

tion of acute renal failure in traumatic rhabdomyo-

lysis. Arch Intern Med 144:277, 1984.

173. Wait RB,Kahng KU: Renal failure complicating obs-

tructive jaundice. Am J Surg 157:256-263, 1989.

174. Plusa SM, Clark NW: Prevention of postoperative

renal dysfunction in patients with obstructive jaun-

dice: A comparison of mannitol-induced diuresis

and oral sodium taurocholate. J R Coll Surg Edinb

36:303-305, 1991.

175. Gubern JM, Martinez-Rodenas F, Sitges-Serra A:

Use of mannitol as a measure to prevent postope-

rative renal failure in patients with obstructive jaun-

dice. Am J Surg 159:444-445, 1990.

176. Zager RA: Sepsis-associated acute renal failure: Some

potential pathogenetic and therapeutic insights.

Nephrol Dial Transplant 4:164-167, 1994.

177. Cumming AD, Driedger AA, McDonald JW, et al:

Vasoactive hormones in the renal response to sys-

temic sepsis. Am J Kidney Dis 11:23-32, 1988.

178. Badr KF: Sepsis-associated renal vasoconstriction:

Potential targets for future therapy. Am J Kidney

Dis 20:207-213, 1992.

179. Cumming AD, McDonald JW, Lindsay RM, et al:

The protective effect of thromboxane synthetase

inhibition on renal function in systemic sepsis. Am

J Kidney Dis 13:114-119, 1989.

180. Garella S, Matarese RA: Renal effects of prostaglan-

dins and clinical adverse effects of nonsteroidal

anti-inflammatory agents. Medicine 63:165-181,

1984.

181. Bone RC, Fisher CJ, Clemmer TP, et al: A controlled

clinical trial of high-dose methylprednisolone in

the treatment of severe sepsis and septic shock.

N Engl J Med 317:653-658, 1987.

182. Veteran’s Administration Systemic Sepsis Coopera-

tive Study Group: Effect of high-does glucocorti-

coid therapy on mortality in patients with clinical

signs of systemic sepsis. N Engl J Med 317:659-665,

1987.

183. Slotman GJ, Fisher CJJ, Bone RC, et al: Detrimental

effects of high-dose methylprednisolone sodium

succinate on serum concentrations of hepatic and

renal function indicators in severe sepsis and septic

shock. The Methylprednisolone Severe Sepsis Study

Group. Crit Care Med 21:191-195, 1993.

184. Rudis MI, Basha MA, Zarowitz BJ: Is it time to

reposition vasopressors and inotropes in sepsis?

Crit Care Med 24:525-537, 1996.

185. Weber A, Schwieger IM, Poinsot O, et al: Sequential

changes in renal oxygen consumption and sodium

transport during hyperdynamic sepsis in sheep.Am

J Physiol 262(RFEP 31): F965, 1992.

186. Lherm T, Troche G, Rossignol M, et al: Renal effects

of low-dose dopamine in patients with sepsis syn-

drome or septic shock treated with catecholamines.

Intens Care Med 22:213-219, 1996.

187. Bellomo R, Chapman M, Finfer S, et al: Low-dose

dopamine in patients with early renal dysfunction:

A placebo-controlled randomised trial. Australian

and New Zealand Intensive Care Society (ANZICS)

Clinical Trials Group. Lancet 356:2139-2143, 2000.

188. Smithies M, Yee TH, Jackson L, et al: Protecting the

gut and the liver in the critically ill: Effects of

dopexamine. Crit Care Med 22:789-795, 1994.

189. Hesselvik JF, Brodin B: Low-dose norepinephrine in

patients with septic shock and oliguria: Effects on

afterload, urine flow and oxygen transport. Crit

Care Med 17:179-180, 1989.

190. Landry DW, Oliver JA: The pathogenesis of vasodi-

latory shock. N Engl J Med 345:588-595, 2001.

191. Argenziano M, Choudri AF, Oz MC, et al: A pros-

pective randomized trial of arginine vasopressin

in the treatment of vasodilatory shock after left

ventricular assist device placement. Circulation

96(Suppl II):II-286-II-290, 1997.

192. Landry DW, Levin HR, Gallant EM, et al: Vasopres-

sin deficiency contributes to the vasodilation of

septic shock. Circulation 95:1122-1125, 1997.

193. Landry DW, Levin HR, Gallant EM, et al: Vasopres-

sin pressor hypersensitivity in vasodilatory septic

shock. Crit Care Med 25:1279-1282, 1997.

194. Russell JA, Walley KR, Singer J, et al: Vasopressin

versus norepinephrine infusion in patients with

septic shock. N Engl J Med 358:877-887, 2008.

242

Fisiología y anestesia